Experts are concerned a shortage of the antibiotic could prove to be troublesome in the coming winter months.
Sander Flaum discusses the DISARM act and how we can fight back against antibiotic resistance.
Novartis sees single-digit growth with new CEO; J&J takes $13.6b charge in the wake of the new tax law; New York City invests in biotech
Drugmakers to remove incentives for sales reps marketing antibiotics; Mylan CEO defends EpiPen pricing; fitness trackers don’t help people lose weight
Some U.S. hospitals still haven’t received Valeant discounts; U.N. General Assembly will discuss antibiotic resistance; AstraZeneca diabetes drugs lowered blood sugar in study
England’s NHS delays hep-C coverage due to pricing; Google reports 21% revenue growth; U.S. and U.K. announce partnership for antibiotic development
Hospitals struggle with high drug costs; the FDA approves new weight loss device; the ADA asks docs not to tweet, but they did anyway
The goal is to develop medications that move beyond the high-toxicity and low-efficacy profiles of older drugs.
The Medicines Company’s commercial lead for infection disease care talks about its breakthrough antidote for carbapenem-resistant enterobacteriaceae.
MM+M Transform: The Patient, Provider and Payer Engagement Matrix provides the most in-depth look at the marketing and technology trends likely to influence the industry’s growth over the next year.
Get the most out of
Register for free and enjoy unlimited access to: